Indications |
Intravenous Malignant blood disorders Adult: Initially: 175-300 mg/m2 given in divided doses over 3-7 consecutive days via IV infusion over 30-60 minutes. Maintenance: 25-100 mg/m2 in a single infusion every 3-4 wk. |
Contraindications |
Pregnancy, lactation; CV disease. |
Warnings / Precautions |
Myocardial irradiation and use of radiotherapy. Hepatic or renal impairment. Elderly. |
Adverse Reactions |
Nausea, vomiting, mucositis, irritant to tissue, sore mouth, bone-marrow suppression, hyperuricaemia. Alopoecia (rare). Potentially Fatal: Cardiotoxicity (rare), myelosuppression in patients who received mitomycin or a nitrosourea, leucopenia. |
Drug Interactions |
Other cardiotoxic drugs e.g. daunorubicin or cyclophosphamide, live vaccines; decreases effects of digoxin, oral anticoagulants, phenytoin and suxamethonium. See Below for More aclarubicin Drug Interactions |
Lab Interactions |
Elevated bilirubin level. |
Mechanism of Actions |
Aclarubicin is an anthracycline, a cytotoxic antibiotic, and inhibits RNA synthesis through intercalation. Distribution: Rapidly distributed into tissues after IV admin. Metabolism: Extensively metabolised. Excretion: Triphasic clearance. Terminal elimination half-life: About 3 hr. Excreted in urine mainly as metabolites. |
ATC Classification |
L01DB04 - aclarubicin ; Belongs to the class of cytotoxic antibiotics, anthracyclines and related substances. Used in the treatment of cancer. |
Available As |
|
Aclarubicin
Post Review about Aclarubicin Click here to cancel reply.
Aclarubicin Containing Brands
Aclarubicin is used in following diseases
Drug - Drug Interactions of Aclarubicin
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.